Literature DB >> 11137522

Th 1 cytokine production by peripheral blood mononuclear cells in X-linked adrenoleukodystrophy.

N Merendino, C Avellino, M Cappa, S Salvati.   

Abstract

Cerebral adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN) are the two most frequent clinical phenotypes of the same genetic defect leading to the accumulation of very long chain fatty acids (VLCFA). Previous studies have suggested that inflammatory cytokines may play a role in the cerebral demyelination and in phenotype expression of the disease. We analyzed cytokine production by stimulated peripheral blood mononuclear cells (PBMC) from 17 patients (four asymptomatic subjects, eight AMN and five ALD). Our results show that lipopolysaccarides (LPS) stimulated PBMC from both symptomatic and asymptomatic patients have an increased production of IL-12 and TNFalpha compared to controls, while after phitoemoagglutinin (PHA) stimulation we observed a decreased production of IL-6 and IL-10. These data indicate that, following an immunological stimulus, PBMC from patients have an increased production of cytokines typical of a Th1 cell response which is able to promote the inflammatory process. This characteristic profile of cytokine production could be related to the biochemical defect and could have a role in central nervous system (CNS) pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11137522     DOI: 10.1016/s0022-510x(00)00469-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Adrenal steroids in adrenomyeloneuropathy. Dehydroepiandrosterone sulfate, androstenedione and 17alpha-hydroxyprogesterone.

Authors:  Maria Wichers-Rother; Andreas Grigull; Piotr Sokolowski; Birgit Stoffel-Wagner; Wolfgang Köhler
Journal:  J Neurol       Date:  2005-12       Impact factor: 4.849

2.  Lipid homeostasis and inflammatory activation are disturbed in classically activated macrophages with peroxisomal β-oxidation deficiency.

Authors:  Ivana Geric; Yulia Y Tyurina; Olga Krysko; Dmitri V Krysko; Evelyn De Schryver; Valerian E Kagan; Paul P Van Veldhoven; Myriam Baes; Simon Verheijden
Journal:  Immunology       Date:  2017-10-26       Impact factor: 7.397

Review 3.  Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathology.

Authors:  Inderjit Singh; Avtar K Singh; Miguel A Contreras
Journal:  J Child Neurol       Date:  2009-07-15       Impact factor: 1.987

4.  Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts.

Authors:  Takuhiro Uto; Miguel A Contreras; Anne G Gilg; Inderjit Singh
Journal:  Dev Neurosci       Date:  2009-01-07       Impact factor: 2.984

Review 5.  Peroxisomes in Immune Response and Inflammation.

Authors:  Francesca Di Cara; Pierre Andreoletti; Doriane Trompier; Anne Vejux; Margret H Bülow; Julia Sellin; Gérard Lizard; Mustapha Cherkaoui-Malki; Stéphane Savary
Journal:  Int J Mol Sci       Date:  2019-08-08       Impact factor: 5.923

Review 6.  The Role of Oxidative Stress and Inflammation in X-Link Adrenoleukodystrophy.

Authors:  Jiayu Yu; Ting Chen; Xin Guo; Mohammad Ishraq Zafar; Huiqing Li; Zhihua Wang; Juan Zheng
Journal:  Front Nutr       Date:  2022-04-08

7.  X-linked adrenoleukodystrophy: very long-chain fatty acid metabolism is severely impaired in monocytes but not in lymphocytes.

Authors:  Franziska D Weber; Christoph Wiesinger; Sonja Forss-Petter; Günther Regelsberger; Angelika Einwich; Willi H A Weber; Wolfgang Köhler; Hannes Stockinger; Johannes Berger
Journal:  Hum Mol Genet       Date:  2013-12-20       Impact factor: 6.150

8.  Enhanced production of nitric oxide, reactive oxygen species, and pro-inflammatory cytokines in very long chain saturated fatty acid-accumulated macrophages.

Authors:  Naotake Yanagisawa; Kazunori Shimada; Tetsuro Miyazaki; Atsumi Kume; Yohei Kitamura; Katsuhiko Sumiyoshi; Takashi Kiyanagi; Takafumi Iesaki; Nao Inoue; Hiroyuki Daida
Journal:  Lipids Health Dis       Date:  2008-11-28       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.